This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of stomach위의 악성신생물 (위암)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: C16 / Special Copayment Reduction: V193 / 5% copayment (for 5 years from the date of cancer registration)
B. SynonymsGastric cancer, gastric adenocarcinoma, Stomach cancer
C. Adult onsetVery high — mainly in the 50s–70s; Korean national screening covers age 40 and over; about twice as common in men as in women
1. HistoryHistory of gastric cancer, discovery of H. pylori (1983 Marshall/Warren), introduction of national gastric cancer screening in Korea, establishment of D2 surgery
2. CausesH. pylori infection (IARC Group 1), smoking, salty foods and smoked processed meats, alcohol, family history
3. GeneticsCDH1, RHOA, ARID1A, TP53 and KRAS mutations, HER2 amplification, TCGA molecular subtypes, hereditary diffuse gastric cancer
4. General epidemiologyMost common cancer in Korea excluding thyroid cancer; about 29,000 cases per year; 5th in incidence worldwide, with overwhelmingly high incidence in East Asia
5. PathophysiologyCorrea cascade: H. pylori → chronic gastritis → atrophy → intestinal metaplasia → dysplasia → cancer (intestinal type); diffuse type involves CDH1
6. SymptomsAsymptomatic early on, epigastric discomfort, loss of appetite, weight loss, nausea, melena, early satiety
7. SignsEpigastric mass, Virchow's node, ascites, Sister Mary Joseph nodule, elevated CEA and CA19-9
8. ScreeningNational cancer screening: upper endoscopy or upper GI series every 2 years from age 40; H. pylori testing and eradication
9. DiagnosisUpper endoscopy + biopsy, CT, EUS, PET-CT, TNM (AJCC 8th edition), HER2/MMR/PD-L1 testing
10. TreatmentD2 gastrectomy, ESD/EMR, FOLFOX and capecitabine + oxaliplatin, trastuzumab, CheckMate-649, KEYNOTE-811
11. Prognosis5-year survival stage I 90%+, stage II 60–70%, stage III 30–50%, stage IV 5–10%; early detection is key
12. PreventionH. pylori eradication, smoking cessation, low-salt diet, vegetable and fruit intake, participation in national gastric cancer screening
13. ReferencesJanjigian YY et al. Lancet 2021 (CheckMate-649) and 9 other papers

1. History

Gastric cancer (gastric adenocarcinoma) is a cancer with a long history worldwide. Clinical descriptions of dysphagia and gastric tumors existed before the 19th century, but diagnosis of gastric cancer in the modern sense began in the late 19th century with the development of endoscopy and gastric surgery. In 1881 Billroth performed the first successful gastrectomy (pylorectomy, Billroth I), and in 1885 total gastrectomy was also attempted. As gastric surgical techniques subsequently developed, surgery remained the center of gastric cancer treatment until the mid-20th century.

The most historic turning point was the discovery of Helicobacter pylori (H. pylori) by Barry Marshall and Robin Warren in 1983. They proved that gastric ulcers and gastritis are caused by bacteria and received the 2005 Nobel Prize in Physiology or Medicine. This was followed by the classification of H. pylori by IARC (International Agency for Research on Cancer) as a definite carcinogen (Group 1) for gastric cancer and the establishment of H. pylori eradication as a gastric cancer prevention strategy. In Korea, the national cancer screening program began in 1996, systematizing gastric cancer screening, and upper endoscopy or upper GI series every 2 years from age 40 was later standardized.

In Japan and Korea, D2 lymph node dissection (D2 gastrectomy) for gastric cancer became the standard procedure from the 1970s–80s, showing superior local control compared with D1 resection in the West. Since the 2000s, with the arrival of HER2-targeted therapy (trastuzumab, ToGA study 2010), ramucirumab (VEGFR2, RAINBOW/REGARD studies) and, in the 2020s, immune checkpoint inhibitors (CheckMate-649: nivolumab; KEYNOTE-811: pembrolizumab + trastuzumab), gastric cancer treatment has entered the era of targeted and immunotherapy.


2. Causes

Helicobacter pylori (H. pylori) infection is the most important cause of gastric cancer. IARC has classified H. pylori as a definite carcinogen (Group 1 carcinogen) for gastric adenocarcinoma. Worldwide, about 60–70% of gastric cancers are estimated to be attributable to H. pylori infection. In Korea, the H. pylori infection rate is about 50% of adults, which is associated with the high incidence of gastric cancer. H. pylori causes chronic inflammation of the gastric mucosa and induces carcinogenesis through reactive oxygen species production, DNA damage and promotion of cell proliferation in gastric epithelial cells. CagA-positive (cagA+ strains) H. pylori are particularly carcinogenic.

Among dietary factors, salty foods (salted vegetables, salted fermented seafood, pickled vegetables) and smoked and processed meats increase gastric cancer risk. A high-salt diet directly irritates the gastric mucosa and promotes the formation of nitrites and nitrosamines. In contrast, abundant intake of fresh vegetables and fruit, especially antioxidants (vitamins C and E, carotenoids), lowers gastric cancer risk. Smoking increases gastric cancer risk 1.5–2-fold and is particularly associated with lesions of the gastric cardia and lesser curvature. Alcohol consumption is also an independent risk factor. With a family history (gastric cancer in a first-degree relative), the risk is increased 2–3-fold. Obesity is also associated with cancer of the gastric cardia. Pernicious anemia (autoimmune atrophic gastritis) is rare but increases gastric cancer risk.

Among hereditary gastric cancers, hereditary diffuse gastric cancer (HDGC) is caused by germline mutations of the CDH1 (E-cadherin) gene, and somatic CDH1 mutations are also common in sporadic diffuse-type gastric cancer. Lynch syndrome (HNPCC) is also a hereditary predisposition that increases gastric cancer risk.


3. Genetics

The molecular genetics of gastric cancer was classified into four molecular subtypes by The Cancer Genome Atlas (TCGA) study (2014): EBV-positive (about 9%, frequent PIK3CA mutations, PD-L1 overexpression, MMR proficient), MSI-H (microsatellite instability-high) (about 22%, MLH1 promoter methylation, hypermutation, favorable prognosis), genomically stable (GS) (about 20%, diffuse type, CDH1 and RHOA mutations, CLDN18-ARHGAP26 fusion) and chromosomal instability (CIN) (about 50%, intestinal type, TP53 mutations, HER2 amplification, RTK/RAS pathway activation). This classification is used for identifying therapeutic targets and predicting prognosis.

Major somatically mutated genes: TP53 (most common in the CIN type, 50–60%), CDH1 (characteristic of the GS type and diffuse type), RHOA (a GS type–specific mutation), ARID1A (frequent in the MSI and EBV types, 10–15%), PIK3CA (high in the EBV and MSI types, 15–20%), KRAS (CIN type, 10%) and FGFR2 amplification (6–10%). HER2 (ERBB2) amplification is observed in about 15–20% of all gastric cancers (especially adenocarcinomas of the gastroesophageal junction and cardia) and is the direct basis for trastuzumab-targeted therapy. VEGFR2 overexpression is the basis for ramucirumab therapy.

Hereditary gastric cancer: hereditary diffuse gastric cancer (HDGC) is caused by germline CDH1 mutations, and prophylactic gastrectomy is recommended. The lifetime risk of gastric cancer in CDH1 mutation carriers is reported as 67% in men and 83% in women. In Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations), colorectal cancer risk is predominant, but gastric cancer risk is also increased by 10–15%. Pharmacogenomically, DPYD variants are associated with 5-FU toxicity and UGT1A1 variants with irinotecan toxicity.


4. General epidemiology

Gastric cancer occurs in more than about 1 million people worldwide each year. In Korea, gastric cancer is the most common cancer excluding thyroid cancer; according to National Cancer Center data, about 29,000 cases occur each year (10.6% of all cancers as of 2022), and the age-standardized incidence is about 32 per 100,000 population (among the highest in the world). It is about 2.1 times more common in men than in women and is concentrated in the 50s–70s. Gastric cancer before age 40 is rare but is often of the diffuse type and has a poor prognosis.

Geographically, East Asia (Korea, Japan, China) has the highest incidence of gastric cancer in the world, owing to a combination of H. pylori infection rates, dietary habits (high-salt diet, fermented foods) and genetic predisposition. In contrast, incidence is low in North America, Western Europe and Oceania. In Korea and Japan, thanks to national screening programs, the rate of detection of early gastric cancer is rising (about 70% diagnosed early in Korea), contributing to improved survival. The incidence trend in Korea has been gradually declining over the past 10 years, but a sharp decrease in the absolute number of cases is limited by the growing elderly population.

Worldwide, the geographic imbalance in gastric cancer incidence is pronounced, and incidence is also relatively high in Eastern Europe (Russia, Poland) and parts of Southeast Asia. The spread of H. pylori eradication therapy is expected to contribute to reducing gastric cancer risk.


5. Pathophysiology

The pathogenesis of gastric cancer is distinguished by histologic subtype. Correa cascade of intestinal-type gastric cancer: the multistep carcinogenic process proposed by Pelayo Correa, progressing in the order H. pylori infection → chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → invasive adenocarcinoma. Each step may be reversible or irreversible, and progression of atrophic gastritis and intestinal metaplasia can be slowed by H. pylori eradication. The CagA toxin of H. pylori is injected directly into gastric epithelial cells and activates the SHP2-ERK, PI3K-AKT and NF-κB pathways.

The pathogenesis of diffuse-type gastric cancer differs from that of the intestinal type. Loss of CDH1 (E-cadherin) function is central, and loss of cell–cell adhesion leads to diffuse infiltration of the gastric wall in the form of signet ring cells. RHOA mutations and the CLDN18-ARHGAP26 fusion gene are also characteristic of the GS (diffuse) type. EBV-associated gastric cancer (EBV+ type) is characterized by PIK3CA mutations, extensive DNA methylation (CpG island methylator phenotype, CIMP) and high PD-L1 expression. In MSI-H gastric cancer, loss of MLH1 protein due to MLH1 promoter methylation abolishes mismatch repair function, leading to the accumulation of high-frequency mutations.

Common to all types, angiogenesis (VEGF/VEGFR2), epithelial–mesenchymal transition (EMT), acquisition of invasiveness through MMP activation, and lymphatic and hematogenous metastasis progress. Peritoneal metastasis (peritoneal dissemination) is especially common in diffuse-type gastric cancer, and peritoneal lavage cytology is used to evaluate peritoneal metastasis before surgery.


6. Symptoms

Gastric cancer is mostly asymptomatic or causes only nonspecific symptoms early on, making early detection difficult. The most common early symptom is epigastric discomfort or pain, presenting as postprandial fullness, indigestion or pain in the pit of the stomach. Because this is difficult to distinguish from gastric ulcer or functional dyspepsia, gastric cancer cannot be identified without endoscopy. Weight loss results from loss of appetite, early satiety and the metabolic wasting of cancer and is observed in about 40–50% of patients diagnosed with gastric cancer.

Nausea and vomiting are prominent when tumors near the pylorus impair gastric emptying. Dysphagia occurs with tumors of the gastric cardia or gastroesophageal junction because of narrowing at the junction with the esophagus. Melena or hematemesis indicates bleeding from the tumor surface, and chronic bleeding leads to anemia. An abdominal mass becomes palpable only after gastric cancer is considerably advanced, and at this stage the tumor is often unresectable. Epigastric fullness, increased belching, loss of appetite and fatigue are also common symptoms. With peritoneal metastasis, ascites develops, causing abdominal swelling and abdominal pain. Symptoms due to distant metastasis (bone, lung, liver) also appear in advanced gastric cancer.

In Korea, thanks to the national gastric cancer screening program, the proportion detected early at the asymptomatic stage is very high, at about 70%, which greatly improves treatment outcomes.


7. Signs

Physical examination findings of gastric cancer vary with the degree of progression. In early gastric cancer, there are usually no specific physical findings. Epigastric tenderness or a mass is observed in advanced gastric cancer, and when a mass is palpable, the tumor has often already progressed to T3 or beyond. Virchow's node (left supraclavicular lymphadenopathy) is a classic sign suggesting distant lymph node metastasis of an intra-abdominal tumor. Ascites appears with peritoneal metastasis and is confirmed by abdominal distension, fluid wave and shifting dullness.

Sister Mary Joseph's nodule (umbilical metastatic nodule) is a rare sign suggesting peritoneal or lymphatic metastasis of advanced gastric cancer. Krukenberg tumor is gastric cancer that has metastasized to the ovaries hematogenously or via the peritoneum, presenting as firm bilateral ovarian masses. A palpable anterior rectal mass (Blumer's shelf) on digital rectal examination indicates peritoneal metastasis. Blood tests may show anemia (chronic bleeding, malnutrition), hypoalbuminemia, elevated CEA and CA19-9 (used mainly for follow-up rather than diagnosis), abnormal liver function (liver metastasis) and elevated ALP (bone metastasis). HER2 IHC (3+) or FISH positivity, PD-L1 CPS score and MMR status (MSI-H) are important tests for deciding the course of treatment.

On endoscopy, the Bormann early gastric cancer classification is used for early gastric cancer, including IIa (superficial elevated), IIb (flat) and IIc (superficial depressed), while advanced gastric cancer is classified as Bormann types I–IV. The diffusely infiltrative type (Bormann IV, linitis plastica) has a high false-negative biopsy rate and a poor prognosis.


8. Screening

Korea operates one of the most systematic national gastric cancer screening programs in the world. National gastric cancer screening performs upper endoscopy or an upper GI series (double-contrast barium study) every 2 years in adults aged 40 and older. Screening costs are subsidized by the national and local governments, and both Medical Aid beneficiaries and National Health Insurance enrollees are covered. Among current screening methods, upper endoscopy is preferred because it is more sensitive than the upper GI series in detecting gastric cancer and precancerous lesions.

H. pylori testing and eradication is also central to the primary prevention strategy for gastric cancer. There is randomized controlled trial evidence (2020 Korean H. pylori clinical practice guideline) that H. pylori eradication therapy reduces the risk of gastric cancer by about 12% and lowers the risk of metachronous gastric cancer after endoscopic treatment of early gastric cancer by 24%. After endoscopic treatment of dysplasia or early gastric cancer (ESD), H. pylori testing must be performed, followed by eradication therapy if positive. Eradication success must be confirmed by a test of cure (13C urea breath test, stool antigen test).

With a family history (a first-degree relative with gastric cancer), starting endoscopic screening before age 40 is recommended. Patients with confirmed atrophic gastritis or intestinal metaplasia need regular endoscopic surveillance every 1–2 years. Active education and encouragement of screening participation for high-risk groups (H. pylori infection, smoking, high-salt diet, family history) are important.


9. Diagnosis

Gastric cancer is confirmed by upper endoscopy + tissue biopsy. A suspicious lesion is identified on endoscopy and biopsies are taken from multiple sites (at least 6). In the diffuse type (linitis plastica), the surface mucosa may appear normal, so deep biopsies from multiple sites are needed. EUS (endoscopic ultrasound) is useful for assessing T stage (depth of tumor invasion into the gastric wall) and N stage (regional lymph nodes) and is particularly accurate in distinguishing T1 from T2. EUS is used to determine ESD indications in early gastric cancer.

Abdominal and chest CT is essential for staging and is used to assess distant metastasis (liver, lung, peritoneal metastasis). PET-CT is used as a complement to search for distant metastases not clearly seen on conventional CT, but its sensitivity is lower in signet ring cell gastric cancer because of low FDG uptake. When peritoneal metastasis is suspected, staging laparoscopy + peritoneal washing cytology is added. AJCC 8th edition TNM staging: T1 (mucosa to submucosa), T2 (muscularis propria), T3 (subserosal connective tissue), T4a (serosal invasion), T4b (invasion of adjacent organs); N1 (1–2 nodes), N2 (3–6), N3a (7–15), N3b (16 or more). After histologic examination, HER2 IHC/FISH, PD-L1 CPS, MMR (MLH1·MSH2·MSH6·PMS2) and MSI testing must be performed.

Serum CEA and CA19-9 are used as adjuncts for monitoring treatment response and following recurrence. In gastroesophageal junction (GEJ) cancer, HER2 testing is especially important because the HER2 positivity rate is high.


10. Treatment

Treatment of gastric cancer is determined by stage. Early gastric cancer (T1a, differentiated type, 2 cm or smaller, no ulceration) can be curatively resected by endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR), applying the absolute and expanded endoscopic indication criteria of the Korean Gastric Cancer Association guidelines. H. pylori eradication after ESD lowers the risk of metachronous gastric cancer. The standard surgery for resectable stage I–III gastric cancer is D2 gastrectomy + D2 lymph node dissection. Depending on tumor location, subtotal gastrectomy or total gastrectomy is performed. Laparoscopic and robotic gastrectomy are spreading in early gastric cancer, with noninferior outcomes compared with open surgery.

In resectable advanced gastric cancer, perioperative chemotherapy (perioperative CTx) uses the FLOT regimen (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) in Europe and S-1+cisplatin or capecitabine+oxaliplatin in East Asia. As adjuvant chemotherapy after resection, S-1 alone (Japan) and capecitabine+oxaliplatin or XELOX are used in Korea. Adjuvant chemoradiotherapy is also an option in high-risk patients after surgery (lymph node metastasis after D2 resection).

As first-line treatment of metastatic or recurrent gastric cancer, based on the CheckMate-649 trial (NEJM 2021), nivolumab+FOLFOX (or capecitabine+oxaliplatin) improved OS in PD-L1 CPS≥5 and was established as standard treatment. In HER2-positive gastric cancer, pembrolizumab+trastuzumab+chemotherapy is the first-line standard based on the KEYNOTE-811 trial. Ramucirumab (RAINBOW/REGARD) is used second-line, and TAS-102 and others from third line onward. In MSI-H gastric cancer, pembrolizumab alone or in combination is indicated from the first line.


11. Prognosis

The prognosis of gastric cancer varies greatly with stage at diagnosis. The 5-year relative survival rate for gastric cancer in Korea has improved steadily owing to national screening, and recent reports show a very high overall 5-year survival rate of about 78% (2016–2020, Korea Central Cancer Registry). This reflects the high proportion of early detection and advances in surgical technique and chemotherapy. 5-year survival by stage: stage I about 90–95%, stage II about 60–70%, stage III about 30–50%, stage IV about 5–10%.

Prognostic factors include stage, number of lymph node metastases, resection margin status, histologic differentiation, vascular and lymphatic invasion, H. pylori eradication status, and molecular subtype (HER2 status, MSI-H, EBV+). MSI-H gastric cancer has a good prognosis on its own (excluding high-grade dysplasia and borderline lesions) and responds well to immune checkpoint inhibitors. In HER2-positive gastric cancer, adding trastuzumab prolongs survival (ToGA trial: OS 13.8 months vs. 11.1 months). EBV-positive gastric cancer responds well to immune checkpoint inhibitors owing to PD-L1 overexpression. H. pylori eradication significantly reduces metachronous gastric cancer after endoscopic treatment and improves long-term prognosis.

Patterns of recurrence are peritoneal metastasis (peritoneal dissemination), hematogenous metastasis (liver, lung, bone, brain), and local recurrence (anastomosis, lymph nodes). Prognosis is very poor with peritoneal dissemination, and hyperthermic intraperitoneal chemotherapy (HIPEC) is attempted in selected cases. A multidisciplinary approach to palliative care and quality-of-life management are important in advanced gastric cancer.


12. Prevention

The most important strategy for preventing gastric cancer is H. pylori testing and eradication therapy. According to the guidelines of the Korean College of Helicobacter and Upper Gastrointestinal Research and the Korean Society of Gastroenterology, eradication therapy in H. pylori-positive patients (standard triple therapy: proton pump inhibitor+clarithromycin+amoxicillin, 7–14 days) has a preventive effect against gastric cancer. H. pylori eradication must be performed after endoscopic treatment of early gastric cancer or dysplasia. Confirmation of eradication success is essential, and if it fails, second-line therapy (bismuth quadruple therapy, levofloxacin-based therapy) is given.

Dietary prevention recommends reducing a high-salt diet (excessive intake of salted and fermented foods), increasing fresh vegetables and fruit, and limiting smoked and processed meat. In particular, the association between salty food and gastric cancer risk has been repeatedly confirmed in domestic and international epidemiologic studies. Smoking cessation is effective in lowering gastric cancer risk (especially gastric cardia cancer). Reducing alcohol intake also has an adjunctive preventive effect. Weight management helps prevent gastric cardia and gastroesophageal junction cancers.

Above all, participation in national gastric cancer screening (age 40 and older, upper endoscopy every 2 years) is the most practical and effective preventive means for early detection. With a family history, screening should start before age 40, and surveillance endoscopy is needed when atrophic gastritis or intestinal metaplasia is confirmed. Prophylactic gastrectomy is recommended in CDH1 variant carriers. A preventive effect of aspirin and COX-2 inhibitors against gastric cancer has been suggested in some studies, but routine use is not recommended.


13. References

  1. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649). Lancet. 2021;398(10294):27-40.
  2. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-590 and KEYNOTE-811 randomized clinical trial. JAMA Oncol. 2020;6(10):1571-1580.
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA). Lancet. 2010;376(9742):687-697.
  4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-209.
  5. Evidence-based clinical practice guidelines for Helicobacter pylori infection treatment in Korea, 2020 revision. Korean Society of Gastroenterology · Korean College of Helicobacter and Upper Gastrointestinal Research. 2020.
  6. National Cancer Center. Annual report of the 2022 Korea Central Cancer Registry. Ministry of Health and Welfare and National Cancer Center, 2024.
  7. Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.
  8. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005-1020.
  9. Kim HH, Han SU, Kim MC, et al. Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage I gastric cancer: The KLASS-01 randomized clinical trial. JAMA Oncol. 2019;5(4):506-513.
  10. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378(12):1085-1095.